Product Description
Daprodustat (Jesduvroq), a HIF-PHI, belongs to a novel class of oral medicines for the treatment of anaemia of CKD in adult patients on dialysis. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anaemia, similar to the physiological effects that occur in the human body at high altitude (Sourced from: https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/)
Mechanisms of Action: HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Japan | United States
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia|Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07300111 |
QLG1218-301 | P3 |
Not yet recruiting |
Anemia |
2027-05-01 |
12% |
2025-12-24 |
Primary Endpoints |
NCT05682326 |
ASCEND-P | P3 |
Completed |
Anemia|Kidney Failure, Chronic |
2024-10-18 |
29% |
2025-11-11 |
|
jRCT2041220113 |
jRCT2041220113 | P3 |
Not yet recruiting |
Anemia |
2028-05-17 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/22/2025 |
News Article |
Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer |
|
02/14/2024 |
News Article |
Pharmaceutical Patents Leader Duke Fitch Joins Troutman Pepper's National Health Sciences IP Team |
|
07/20/2023 |
News Article |
Akebia's Vafseo (vadadustat) Poised to Make Waves for GSK's Jesduvroq and FibroGen/Astellas' Evrenzo |
|
03/27/2023 |
News Article |
Familiarity with GSK's Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights |